Fig. 6From: Safety and efficacy of elagolix (with and without add-back therapy) for the treatment of heavy menstrual bleeding associated with uterine leiomyomas: a systematic review and meta-analysisForest plot comparing across interventions the overall incidence of adverse eventsBack to article page